BFNH
Bioforce Nanosciences Holdings, Inc.
$2.02
+0.00 (+0.00%)
At close · Jul 7
Going-concern doubt
— flagged May 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our ability to obtain additional financing, whether through the issuance of additional equity or through the assumption of debt, is uncertain. Accordingly, our independent auditors' report on our financial statements for the year ended December 31, 2025 includes an explanatory paragraph regarding concerns about our ability to continue as a going concern, including additional information contained in the notes to our financial statements describing the circumstances leading to this disclosure.”View the 10-Q filed May 19, 2026
Market Cap
$67.77M
Shares
33,549,005
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard Kaiser | interim Chief Executive Officer | Appointed | 2026-06-18 |
| Scott Mager | Director | Appointed | 2026-06-18 |
| Sasha Shapiro | Vice-President | Resigned | 2026-06-18 |
| John LaViolette | Co-Chief Executive Officer | Resigned | 2026-06-18 |
| Steven Gagnon | Co-Chief Executive Officer | Resigned | 2026-06-18 |